Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07475728 · ClinicalTrials.gov registry record
EMS-Initiated Buprenorphine
A clinical trial, sponsored by Yale University.
- Not yet
- Registry status
- 495
- Enrollment target
NCT07475728: Clinical Trial study, sponsored by Yale University.
NCT07475728 is a clinical trial that has not yet begun recruiting, run by Yale University. The registered enrollment target is 495 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07475728 has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- 495 participants
- Enrollment target
Study Summary
This is a multisite EMS study that will first conduct a sequence of pragmatic, prehospital field studies to provide preliminary feasibility, acceptability, and safety data for refinement and enhancement of a subsequent single-arm prospective trial that will provide preliminary effectiveness data, from which to build a larger randomized control trail (RCT) trial.
Primary Outcome
Feasibility and acceptability will be measured by the proportion of patients who accept EMS-initiated BUP among all patients who are offered the EMS-initiated BUP clinical protocol.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2026-06 |
| Est. Completion | 2029-05 |
What is known before NCT07475728 opens enrollment
NCT07475728 is an observational study that tracks outcomes without assigning an intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07475728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07475728 about?
NCT07475728 is a clinical study titled "EMS-Initiated Buprenorphine". This is a multisite EMS study that will first conduct a sequence of pragmatic, prehospital field studies to provide preliminary feasibility, acceptability, and safety data for refinement and enhancement of a subsequent single-arm prospective trial that will provide preliminary effectiveness data, fr...
What is the current status of trial NCT07475728?
This trial is currently not yet recruiting. The enrollment target is 495 participants. The study started on 2026-06. Estimated completion is 2029-05.
Who is sponsoring clinical trial NCT07475728?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia